LLY

1,014.81

-1.98%↓

JNJ

202.44

-1.54%↓

ABBV

228.37

-0.49%↓

UNH

333.06

-1.2%↓

AZN

90.22

-0.61%↓

LLY

1,014.81

-1.98%↓

JNJ

202.44

-1.54%↓

ABBV

228.37

-0.49%↓

UNH

333.06

-1.2%↓

AZN

90.22

-0.61%↓

LLY

1,014.81

-1.98%↓

JNJ

202.44

-1.54%↓

ABBV

228.37

-0.49%↓

UNH

333.06

-1.2%↓

AZN

90.22

-0.61%↓

LLY

1,014.81

-1.98%↓

JNJ

202.44

-1.54%↓

ABBV

228.37

-0.49%↓

UNH

333.06

-1.2%↓

AZN

90.22

-0.61%↓

LLY

1,014.81

-1.98%↓

JNJ

202.44

-1.54%↓

ABBV

228.37

-0.49%↓

UNH

333.06

-1.2%↓

AZN

90.22

-0.61%↓

Home・Aandelen Lijst・Ventyx Biosciences Inc

Ventyx Biosciences Inc

Open

7.99 2.96

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

7.57

Max

8.04

Belangrijke statistieken
By Trading Economics
Inkomsten	4.2M -23M
Winstmarge	-2,027.003
Werknemers	83
EBITDA	6.6M -23M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+72.67% upside

Marktinformatie
By TradingEconomics
Marktkapitalisatie	82M 669M
Vorige openingsprijs	5.03
Vorige sluitingsprijs	7.99

Ventyx Biosciences Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

3 dec 2025, 23:21 UTC

Winsten

Acquisities, Fusies, Overnames

EQB to Buy Loblaw Unit PC Financial for About $573.5 Million -- Update

3 dec 2025, 23:14 UTC

Acquisities, Fusies, Overnames

EQB to Buy PC Financial From Loblaw for About $573.5 Million

3 dec 2025, 22:01 UTC

Belangrijke Marktbewegers

Costco Wholesale Reports Higher Monthly Sales

3 dec 2025, 21:38 UTC

Winsten

Salesforce Raises Revenue Forecast as Agentforce Sales Top $500 Million

3 dec 2025, 23:59 UTC

Marktinformatie

Australian Coal Prices Seen Having Recovered Well -- Market Talk

3 dec 2025, 23:49 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

3 dec 2025, 23:49 UTC

Marktinformatie

HSBC Chair Appointment Unlikely to Have Material Operational Impact -- Market Talk

3 dec 2025, 23:49 UTC

Marktinformatie

Nikkei May Decline Amid Caution Over U.S. Labor Market -- Market Talk

3 dec 2025, 23:13 UTC

Marktinformatie

Australian Treasurer Says Economy Not On Drip of Govt Spending -- Market Talk

3 dec 2025, 23:10 UTC

Winsten

Salesforce Raises Forecast as Agentforce Sales Top $500M -- Update

3 dec 2025, 23:08 UTC

Marktinformatie

Goodman's New Bull Sees Profit Upgrade on Cards -- Market Talk

3 dec 2025, 23:06 UTC

Acquisities, Fusies, Overnames

EQB to Buy Loblaw Unit PC Financial for About $573.5M -- Update

3 dec 2025, 22:59 UTC

Acquisities, Fusies, Overnames

EQB to Buy PC Financial From Loblaw for About $573.5M

3 dec 2025, 22:45 UTC

Marktinformatie

WiseTech Investor Day Increases Bull's Confidence -- Market Talk

3 dec 2025, 22:20 UTC

Winsten

Salesforce CEO: 9,500 of 18,500 Total Closed Agentforce Deals Are Paid

3 dec 2025, 22:19 UTC

Winsten

Salesforce CEO: Six Out of 10 Biggest Deals in 3Q Came from Agentforce

3 dec 2025, 22:17 UTC

Winsten

Salesforce Working to Add Voice to Agentforce, CEO Says

3 dec 2025, 22:16 UTC

Winsten

Salesforce CEO: Williams-Sonoma's Agentforce Makes Up 60% of Customer Chats

3 dec 2025, 22:15 UTC

Winsten

Salesforce CEO: Agentforce ARR Was $540M in 3Q

3 dec 2025, 22:10 UTC

Acquisities, Fusies, Overnames

EQB: Will Enter Into a Long-Term Strategic Relationship With Loblaw >EQB.T

3 dec 2025, 22:09 UTC

Acquisities, Fusies, Overnames

EQB: Agreed to Acquire PC Fincl From Loblaw >EQB.T

3 dec 2025, 21:50 UTC

Marktinformatie

Auto & Transport Roundup: Market Talk

3 dec 2025, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

3 dec 2025, 21:49 UTC

Winsten

Salesforce Reports Mounting Profits. The Stock Is Rising. -- Barrons.com

3 dec 2025, 21:23 UTC

Winsten

Salesforce Raises Revenue Forecast as Agentforce Sales Top $500M

3 dec 2025, 21:19 UTC

Winsten

Salesforce Reports Mounting Profits. The Stock Is Rising. -- Barrons.com

3 dec 2025, 21:06 UTC

Winsten

Salesforce Reports Mixed Earnings. The Stock Is Rising. -- Barrons.com

3 dec 2025, 21:04 UTC

Winsten

Salesforce Sees Profitable Growth Framework Target of 50 by FY30 >CRM

3 dec 2025, 21:04 UTC

Winsten

Salesforce Targets $60 B Plus Organic Rev by FY30 >CRM

3 dec 2025, 21:03 UTC

Winsten

Salesforce Raises FY26 Oper Cash Flow Growth Guidance to 13% to 14% Y/Y >CRM

Peer Vergelijking

Prijswijziging

Ventyx Biosciences Inc Prognose

Koersdoel

By TipRanks

72.67% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 13.71 USD 72.67%

Hoogste 21 USD

Laagste 2 USD

Gebaseerd op 8 Wall Street-analisten die 12-maands prijsdoelen bieden voor Ventyx Biosciences Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

8 ratings

Buy

Hold

Sell

Gebaseerd op 8 analisten die aandelenratings hebben gegeven aan Ventyx Biosciences Inc - Dist in de afgelopen 3 maanden.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Ventyx Biosciences Inc

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.